Medpace (MEDP) Q3 Results Spotlight Strong Backlog And Sticky Cancellations

Medpace Holdings slipped about 1.3% in regular trading today to roughly $654, a modest pullback after a strong run into this earnings print. That dip came even as the contract research group posted another solid Q3 2026 update, with revenue of $716 million and diluted earnings per share of $4.84 capturing investors’ attention.

Short term traders saw a cool down. Longer horizon holders are likely watching something else entirely. Backlog now sits near $3.2b with $1.99b expected to turn into revenue over the next year, and a fresh $1.0b buyback authorization adds a powerful capital return lever to that multi year story.

Like the strength in Medpace Holdings' backlog and fresh buyback but want more ideas that blend resilient fundamentals with balance sheet support? Check out our screener of list of solid balance sheet and fundamentals stocks (26 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$716.0m vs. US$659.9m (+8.5%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$137.5m vs. US$111.1m (+23.7%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$4.92 vs. US$3.95 (+24.5%)
• EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization, Q3 2026 vs. Q3 2025): US$172.1m vs. US$148.4m (+16.0%), with an EBITDA margin of 24.0% vs. 22.5%

Ask Charlie what Medpace’s record new awards mean for future growth.

Evaluating Medpace’s Bullish Backlog And Awards Story

The optimistic view hangs on Medpace Holdings turning strong bookings into dependable workload and earnings power.

"The main thing that has to go right is that elevated cancellation levels ease or are offset by strong new awards so that backlog coverage and sequential revenue trends stabilise as Medpace Holdings moves through late 2026 and into 2027."

The latest quarter ticks several boxes. Net new awards of US$873.4m and 23.9% growth in awards over the last 12 months lifted backlog to about US$3.2b. Around US$1.99b is slated to convert within 12 months, and Q3 revenue rose 8.5% year on year. Cancellations stayed at the high end of management’s range, so award strength is doing the offsetting work the thesis requires rather than benefiting from a cancellation tailwind.

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for.

Medpace Bear Case: Cancellations Still Cloud Conversion

Bears argue Medpace Holdings is one cancellation cycle away from a weaker revenue engine and shakier earnings quality.

"Although management reports that Q2 2026 cancellations improved from early year peaks, the earlier period of the highest cancellations in over a year and weaker plus one year backlog coverage signals a still fragile pipeline. Any return to elevated cancellations could limit revenue growth and strain earnings visibility."

Q3 results partly validate that worry. Net new awards of US$873.4m and a US$3.2b backlog show clients are still signing contracts. Yet cancellations stayed at the high end of management’s range and one year backlog coverage has only modestly recovered, so the risk around future conversion has not cleared.

Find Earnings Disconnects Early

Medpace Holdings recently highlighted how a full project pipeline and active share repurchases can reshape investor discussion without resolving key disagreements. The real opportunity is exploring stocks that could be undervalued before the wider market focuses on their fundamentals.

• Company 1 - 39% below our estimate - turns lidar from pilot programs into scaled hardware shipments for commercial production customers.
• Company 2 - 50% below our estimate - leans on a regional banking acquisition to expand fee income and deepen partnership-driven cross-selling.
• Company 3 - 33% below our estimate - ties high-performance AI processors to a proprietary software stack that keeps data centre clients closely integrated.

That is three of the list. See all 31 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com